US20170274078A1 - Compositions and methods for treatment of neurological disorders - Google Patents
Compositions and methods for treatment of neurological disorders Download PDFInfo
- Publication number
- US20170274078A1 US20170274078A1 US15/505,039 US201515505039A US2017274078A1 US 20170274078 A1 US20170274078 A1 US 20170274078A1 US 201515505039 A US201515505039 A US 201515505039A US 2017274078 A1 US2017274078 A1 US 2017274078A1
- Authority
- US
- United States
- Prior art keywords
- slurry
- nerve
- nerves
- pain
- ice slurry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Chronic peripheral nerve pain is a common problem in the general population and, in particular, military veterans. It can arise from numerous causes, such as surgery, trauma, neuroma, metabolic or genetic disorder, infection or it can be idiopathic. It is estimated that 20-30% of all extremity injuries in the US military involve peripheral nerve damage. Severe peripheral nerve injury and amputation have devastating effects on quality of life due to intractable neuropathic pain. Treatment of refractory nerve pain has been attempted using oral pain medications, such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), surgical and various percutaneous procedures, including radiofrequency and alcohol ablation. However, there are numerous complications associated with these treatments, including addiction to narcotics and the need for multiple procedures. Overall, current treatment options for chronic peripheral nerve pain fail to provide satisfactory results.
- oral pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs)
- NSAIDs nonsteroidal anti-inflammatory drugs
- Cryoneurolysis is the use of cold to target nerves. Cryoneurolysis is a specialized technique for providing long-term pain relief in interventional pain management settings. The application of cold to nerves creates a conduction block similar to the effect of local anesthetics and, if the nerve is frozen, leads to Wallerian degeneration of the nerve. Cryoneurolysis has been used for many years, albeit sparingly, for treatment of phantom limb pain, pain secondary to trigeminal neuralgia, post-thoracotomy chest wall pain, peripheral neuritis pain, post herpetic neuralgia pain.
- the technique involves a probe 1.4 to 2 millimeters in size that utilizes pressurized gas (e.g., nitrous oxide or carbon dioxide) at 600-800 psi to generate temperatures as cold as ⁇ 89° C. or lower at the tip of the probe through adiabatic cooling under the Joule-Thompson effect, thereby forming an ice ball at the target area.
- pressurized gas e.g., nitrous oxide or carbon dioxide
- the probe is placed directly on the nerve and any tissue that comes into contact with the probe is destroyed due to the extreme cold temperatures used. Because the surrounding tissue is almost always injured or damaged, this procedure is not selective. In addition, the damage to the nerves in these temperature ranges can be permanent.
- the invention provides a method of providing reversible inhibition of peripheral nerves to a subject in need thereof.
- the method comprises providing a biocompatible ice slurry to the peripheral nerves for a duration sufficient to inhibit the peripheral nerves in the subject, wherein the inhibition is reversible. In some embodiments, the inhibition is reversed after about 5 months or less.
- the peripheral nerves targeted for inhibition can be subcutaneous nerves; somatic nerves, including sensory nerves, motor nerves, cranial nerves or spinal nerves;
- the biocompatible ice slurry is provided along the perineural sheath of a peripheral nerve.
- the biocompatible ice slurry comprises ice particles and a lactated Ringer's solution or a lactated electrolyte solution.
- the biocompatible ice slurry further comprises hetastarch or dextrose.
- the biocompatible ice slurry further comprises about 0.1% to about 20% glucose.
- the biocompatible ice slurry further comprises about 0.1% to about 20% glycerol.
- the biocompatible ice slurry further comprises about 0.1% to about 6% hetastarch.
- the biocompatible ice slurry comprises ice particles and saline.
- the biocompatible ice slurry further comprises about 0.1% to about 20% glycerol.
- the biocompatible ice slurry further comprises about 0.1% to about 20% dextrose.
- the biocompatible ice slurry further comprises about 0.1% to about 5% ethanol.
- the biocompatible ice slurry further comprises about 0.1% to about 10% poly vinyl alcohol.
- the biocompatible ice slurry further comprises at least one ion, sugar, polysaccharide, lipid, oil, lysolecithin, amino acid, caffeine, surfactant, anti-metabolite or combinations thereof.
- the at least one ion includes, but is not limited to, calcium, potassium, hydrogen, chloride, magnesium, sodium, lactate, phosphate, zinc, sulfur, nitrate, ammonium, carbonate, hydroxide, iron, barium or combinations thereof, including salts thereof.
- the at least one sugar includes, but is not limited to, glucose, sorbitol, mannitol, hetastarch, sucrose, or combinations thereof.
- the at least one oil includes, but is not limited to, canola oil, coconut oil, corn oil, cottonseed oil, flaxseed oil, olive oil, palm oil, peanut oil, safflower oil, soybean oil, sunflower oil or combinations thereof.
- the surfactant is a detergent.
- the detergent includes, but is not limited to, deoxycholate, sodium tetradecyl sulphate, polidocanol, polysorbate (including polysorbate 20 (polyoxyethylen (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate)), sorbitan ester, poloxamater or combinations thereof.
- the biocompatible ice slurry comprises a peritoneal dialysis solution.
- the biocompatible ice slurry cools the nerves to between about 5° C. and about ⁇ 40° C.
- the biocompatible ice slurry has a first equilibration temperature of between about 4° C. and about ⁇ 30° C.
- the biocompatible ice slurry has a second equilibration temperature of between about 2° C. and about ⁇ 30° C.
- the ice particles are spherical or round with a diameter of about 1 mm to about 0.01 mm.
- the biocompatible ice slurry further comprises an agent including, but not limited to, a vasoconstricting agent, corticosteroid, NSAID, anesthetic, glucocorticoid and a lipoxygenase inhibitor or combinations thereof.
- a vasoconstricting agent includes, but is not limited to, epinephrine or norepinephrine.
- the anesthetic includes, but is not limited to, lidocaine, bupivacaine, prilocaine, tetracaine, procaine, mepivicaine, QX-314 and etidocaine or combinations thereof.
- the biocompatible ice slurry is injected.
- the injection can be administered into or around any peripheral nerves including, but not limited to, the cutaneous nerve, trigeminal nerve, ilioinguinal nerve, intercostal nerve, interscalene nerve, intercostal nerves, supraclavicular nerve, infraclavicular nerve, axillary nerve, paravertebral nerve, transverse abdominis nerve, lumbar plexus nerve, femoral nerve, pudental, celiac plexus and sciatic nerve, any nerve conducting painful sensations or any injured nerve producing pain or disease.
- the biocompatible ice slurry is provided to the peripheral nerves of the subject by tumescent pumping of the slurry.
- pressure is applied at the site of injection to reduce blood flow.
- the tissue comprising the peripheral nerves is cooled externally prior to, during, or after providing the biocompatible ice slurry.
- ice content of the biocompatible ice slurry is monitored by ultrasound or imaging.
- the subject in need of treatment suffers from a disorder including, but not limited to, neuropathic pain, diabetic neuropathy pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, cancer related itch or pain, burn itch or pain, lichen sclerosus, scalp itch, nostalgia parastethica, atopic dermatitis, eczema, psoriasis, lichen planus, vulvar itch, vulvodynia, lichen simplex chornicus, prurigo nodularis, itch mediated by sensory nerves, peripheral neuropathy, peripheral nerve damage, post-thoracotomy pain, incisional pain, chest pain, coccydynia, lower back pain (with or without radiculopathy), scars, neuromas, acute post-operation pain, lumbar facet joint syndrome and cutaneous pain disorder.
- a disorder including, but not limited to, neuropathic pain, diabetic neuropathy pain, tri
- the cutaneous pain disorder includes, but is not limited to, reflex sympathetic dystrophy (RSD), phantom limb pain, neuroma, post herpetic neuralgia, headache, occipital neuralgia, tension headaches and vulvodynia.
- RSD reflex sympathetic dystrophy
- phantom limb pain neuroma
- post herpetic neuralgia headache
- occipital neuralgia tension headaches
- vulvodynia vulvodynia
- the subject in need of treatment suffers from a motor disorder including, but not limited to, hemifacial spasm, bladder spasm, laryngospasm and gustatory hyperhidrosis.
- a motor disorder including, but not limited to, hemifacial spasm, bladder spasm, laryngospasm and gustatory hyperhidrosis.
- FIG. 1 depicts a quantitative model to illustrate the behavior of injected slurries.
- FIG. 2 depicts three stages of heat exchange following infusion of a slurry into a tissue.
- FIG. 3 depicts a rat sciatic nerve, exposed via surgical dissection.
- FIG. 4 depicts a thermocouple placed under a rat sciatic nerve to record tissue temperature.
- FIG. 5 depicts tissue temperature following injection of a 6% hetastarch lactated ringer slurry on top of a live rat sciatic nerve.
- FIG. 6 depicts tissue temperature following injection of a 6% hetastarch lactated ringer slurry on top of a live rat sciatic nerve.
- FIG. 7 depicts tissue temperature following injection of a 6% hetastarch lactated ringer slurry on top of a live rat sciatic nerve.
- FIG. 8 depicts the blunt exposure of the common sciatic nerve through the biceps femoris and separation from adjacent tissue.
- FIG. 9 depicts the injection of ice slurry.
- FIG. 10 depicts the thermal paw withdrawal latencies of rats with chronic constriction sciatic nerve injury. Following the constriction sciatic nerve injury, responder rats were either treated with slurry or left untreated (nonslurry). Increase in thermal withdrawal latency response times to a heat exposure in rats exposed to the slurry at 20, 25, and 42 days post-slurry was observed indicating decreased pain to thermal stimuli.
- FIG. 11 depicts testing results by comparing differences in thermal withdrawal latencies of responder rates with normalization to internal control.
- FIG. 12 depicts the effect of increasing glycerol concentrations (in normal saline) on slurry temperatures.
- FIG. 13 verifies the blind injection of an ice slurry stained with tattoo ink for visualization adjacent to the rat sciatic nerve.
- FIG. 14 depicts the thermal paw withdrawal latencies of rats with chronic constriction sciatic nerve injury scored as “severe.” Differences in paw withdrawal latencies from baseline after injection of room temperature and ice slurries show that ice slurry induces decreased pain sensation after the injury.
- FIG. 15 depicts the thermal paw withdrawal latencies of rats with chronic constriction sciatic nerve injury scored as “moderate.” Differences in paw withdrawal latencies from baseline after injection of room temperature and ice slurries show that ice slurry induces decreased pain sensation after the injury.
- FIG. 16 depicts the thermal paw withdrawal latencies of rats with chronic constriction sciatic nerve injury scored as “mild.” Differences in paw withdrawal latencies from baseline after injection of room temperature and ice slurries show that ice slurry induces decreased pain sensation after the injury.
- FIG. 17 depicts methods of removing slurry.
- FIG. 18 depicts the difference in thermal withdrawal latencies of the left hindpaw at time of follow-up as compared to baseline measurements. A positive value indicates an increased tolerance for thermal pain due to decreased sensation.
- FIG. 19 depicts mean thermal withdrawal latency of rats injected with slurries. Slurries were injected through a needle around the left sciatic nerve and the right sciatic nerve was left untreated to serve as control.
- biocompatible refers to a substance or solution having the capability of coexistence with living tissues or organisms without causing harm.
- ice refers to the solid state of water (i.e., frozen water).
- water refers to H 2 O and all isotopes of H 2 O, including D 2 O, T 2 O, etc., and mixtures thereof.
- aqueous solution/aqueous slurry refers to a solution/slurry containing H 2 O and all isotopes of H 2 O, including D 2 O, T 2 O, etc., and mixtures thereof.
- solutions may include water in its solid, semi-solid and/or liquid states.
- the term “equilibrium” or “equilibrium temperature” refers to a temperature that is between the temperatures of a slurry and a tissue at the time of initial contact between the slurry and the tissue.
- reversible inhibition of peripheral nerves refers to a loss of function in the nerve which is recovered over time. Loss of function would include, for example, decreased thermal or mechanical sensation in the nerve.
- Ranges provided herein are understood to be shorthand for all of the values within the range.
- a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
- a “slurry” refers to solid phase particles (e.g., ice particles) suspended in a biocompatible liquid phase solution.
- the slurry may also contain gas phase bubbles.
- a “subject” is a vertebrate, including any member of the class mammalia, including humans, domestic and farm animals, and zoo, sports or pet animals, such as, e.g., horse, cat, dog, mouse, rabbit, pig, sheep, goat, cattle and higher primates.
- the terms “treat,” “treating,” “treatment” and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
- the invention involves introducing a composition comprising a cold slurry (e.g., ice slurry) into interstitial tissue, i.e., directly into the tissue rather than through a natural conduit of the body such as arteries, veins, or gut.
- a cold slurry e.g., ice slurry
- interstitial tissue i.e., directly into the tissue rather than through a natural conduit of the body such as arteries, veins, or gut.
- Gradual warming occurs by a combination of heat diffusion from surrounding warm tissue and by convective heating from blood flow.
- Blood flow can be reduced in the local tissue by pressure or by drugs, e.g., blood flow can be stopped or greatly reduced by applying pressure to the cold tissue or by addition of epinephrine or other vasoconstrictor agent(s) to the slurry.
- the desired level of pain relief may depend on temperature, rate of cooling, duration of cooling and the number of cooling cycles.
- Effectiveness of treatment is related to the amount of lipid crystallization, amount and number of epidermal nerve fiber and dermal myelinated nerve fiber reduction, the minimum temperature achieved, the duration of cold temperatures, and the number of cold cycles (slurry injections can be easily repeated in one treatment session). All of these parameters can be controlled in a local tissue volume, by varying the amount and rate of introduction, of slurries containing various fractions of ice content.
- slurry components including liquid and cooled particle content (e.g., ice content), and application parameters, including placement, rate and volume of infusion
- predictable target tissue cooling can be attained.
- the temperature of the slurry is at or near the melting point, keeping the slurry cold during and after infusion into tissue.
- this melting temperature can be chosen for desired effects on the tissue, over a range from about ⁇ 30 to about 10° C., in particular, over a range from about ⁇ 30° C. to about 4° C., more in particular, over a range from about ⁇ 30° C. and to about 2° C.
- the temperature of the solution comprising the slurry can be adjusted by selection of liquid phase components, including various solvents and solutes and ions that produce a controlled freezing point depression (e.g., including aqueous solutions of NaCl and other biocompatible salts, other electrolytes such as potassium or chloride, glycerol, sugars, polysaccharides, lipids, surfactants, anti-metabolites and detergents).
- liquid phase components including various solvents and solutes and ions that produce a controlled freezing point depression (e.g., including aqueous solutions of NaCl and other biocompatible salts, other electrolytes such as potassium or chloride, glycerol, sugars, polysaccharides, lipids, surfactants, anti-metabolites and detergents).
- the solution comprising the slurry can include, or consist essentially of, a lactated Ringer's solution or a saline solution or hetastarch solution.
- Slurry formulations can be made with dextrose, mannitol, glucose, sorbitol, mannitol, hetastarch, sucrose, glycerol or ethanol or poly vinyl alcohol. Freezing point depression to about ⁇ 40° C. can be achieved with saline, glycerol, glucose, sorbitol, or mixtures thereof.
- slurry formulations can be made with about 0.1% to about 5% ethanol or about 0.1% to about 20% glycerol (e.g., in particular, about 5% to about 10% glycerol).
- the solution comprising the slurry refers a lactated Ringer's solution with or without about 0.1% to about 20% glucose or glycerol; saline with or without about 0.1% to about 20% dextrose or glycerol; or a lactated Ringer's solution in 6% hetastarch.
- the solution comprising the slurry can include about 0.1% to about 6% hetastarch in a lactated electrolyte solution.
- Glycerol is desirable for cryoprotection and/or use as a surfactant. Freezing point depressions for glycerol-water solutions can be achieved as described below in Table 1.
- Ions that can be included in the slurry to produce a controlled freezing point depression include, but are not limited to calcium, potassium, hydrogen, chloride, magnesium, sodium, lactate, phosphate, zinc, sulfur, nitrate, ammonium, carbonate, hydroxide, iron, barium or combinations thereof, including salts formed thereof.
- the solution comprising the slurry can include vasoconstricting agents that reduce local tissue blood flow.
- vasoconstricting agents include, but are not limited to, epinephrine (e.g., 1/10,000 or less) and norepinephrine.
- Blood flow can also be decreased by use of tourniquet, pressure/compression, and suction of the area to be treated.
- Vasoconstriction can also be achieved by precooling the tissue to be treated with topical application of cold in a form of Peltier cooling or application of ice or cold pack to the surface of the skin.
- Suitable surfactant molecules include, but are not limited to, sodium tetradecyl sulphate, polysorbate, polysorbate 20 (polyoxyethylen (20) sorbitan monolaurate), polyoxyethylene sorbitan monooleate, sorbitan monooleate polyoxyethylene sorbitan monolaurate, lecithin, and polyoxyethylene-polyoxypropylene copolymers, polysorbate, polysorbate 20 (polyoxyethylen (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan ester, poloxamater or combinations thereof.
- lysolecithin is known to cause reversible degeneration of non-myelinated axons (Mitchell J. Degeneration of Non-myelinated Axons in the Rat Sciatic Nerve Following Lysolecithin Injection. Acta Neuropathol (Berl) (1982) 56:187-193). This combination will allow targeting of myelinated and non-myelinated nerve fibers through slurry injection and thus lead to complete nerve block.
- the solution comprising the slurry can include detergents that can function as freezing point depressants or agents to dissolve myelin sheaths.
- detergents include, but are not limited to, TWEEN® polysorbates, deoxycholate, cholate, phosphatidyl choline and sodium deoxycholate. Exemplary slurry formulations are shown in Table 2.
- the solution comprising the slurry can include agents to reduce inflammation, including but not limited to, corticosteroids, glucocorticoids, lipoxygenase inhibitors, and NSAIDs.
- the solution comprising the slurry can include anesthetic agents to further reduce pain, including but not limited to, polidocanol, lidocaine, bupivacaine, prilocaine, tetracaine, procaine, mepivicaine and etidocaine.
- anesthetic agents to further reduce pain, including but not limited to, polidocanol, lidocaine, bupivacaine, prilocaine, tetracaine, procaine, mepivicaine and etidocaine.
- the anesthetic is QX-314, N-ethyl bromide, a quaternary lidocaine derivative that is a permanently charged molecule capable of providing long term (over 24 hours) anesthesia.
- QX-314 can provide more selective blocking of nociceptors and with longer duration of action and less side effects.
- QX-314 is a charged molecule that needs to enter the cell and block the sodium channels intracellularly. The ability of QX-314 to block from the inside but not the outside of neuronal membranes could be exploited to block only desired neurons. Combining QX-314 with the cold slurry injections described herein can selectively target cold sensing nociceptive sensory neurons to provide selective and long lasting anesthesia.
- the slurry can be composed of a lipid emulsion, such as, e.g., Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations.
- lipid emulsions can be mixed with amino acids and dextrose as part of a total nutrient admixture.
- the slurry can be composed of a peritoneal dialysis solution.
- the solution comprising the slurry can include cooled particles such as, e.g., ice particles in sizes smaller than the inner diameter of medical cannulas, catheters, and needles, e.g., smaller than about 1 mm and preferably smaller than about 0.1 mm.
- the volume percent, size and/or shape of cooled particles (preferably less than about 0.5 mm and nominally spherical or ovoid) can be adjusted to optimize flow of the slurry through needles catheters or cannulas and flow through the various target tissues during infusion. See, for example, Kauffeld, M et al. Int J Refrig. 2010. 33(8): 1491-1505.
- the volume percentage of cooled particle (e.g., ice particle) within the infused slurry and the volume of infused slurry determine cooling capacity of the infusion.
- the volume percentage of ice within the infused slurry can range from about 0.1% to about 50% of the solution.
- the slurry In a given volume of target tissue into which a slurry is infused, there are three stages of heat exchange. Initially, the slurry is much colder than the tissue as it infuses into and/or through the tissue. There is a strong thermal gradient between the tissue and the slurry that rapidly equilibrates until a local equilibrium temperature is achieved. During this rapid equilibration stage, the slurry ice melts. The amount of melting that occurs depends on the initial ice content, the local volume fraction of slurry that is mixed with tissue, the starting tissue temperature, tissue lipid content, and other factors including the slurry infusion volume and rate. These factors can be modeled using classical and numerical fluid and heat transfer approximations, e.g., with finite element models (See Example 1).
- the equilibration temperature will be very close to the melting point of ice in the slurry, i.e., it can be from about ⁇ 20° C. to about 4° C.
- the composition of the slurry fluid component sets the low temperature limit for this equilibration temperature, i.e., the equilibration temperature cannot be lower than depressed melting point of ice in the slurry.
- the second stage begins in which ice continues to melt as heat is removed from surrounding tissues.
- This second stage can last for seconds to many minutes, depending on many factors. These factors include the amount of ice per unit volume that remains after the initial equilibration, dimensions of the tissue volume that contains ice, heat transfer and composition of the target and surrounding tissues, and local blood flow.
- the second stage can be viewed as providing a “treatment temperature and treatment time” for a target tissue, because temperature remains relatively stable in the target tissue during this time, until all of the slurry ice has melted.
- Treatment temperature is set mainly by composition of the slurry liquid, and volume fraction of slurry that is infused into and around the target tissue.
- Treatment time is set mainly by ice content and infusion variables including volume, rate and distribution, and by the size and shape of the target tissue, and by blood flow in the target tissue.
- a greater content of slurry ice will extend the second stage; a greater infused slurry volume fraction (ratio of local infused slurry to target tissue and infused slurry) will extend this second stage; a large dimension of the infused slurry-and-target tissue will extend this stage approximately in proportion to the square of the dimension; and blood flow in the target tissue will reduce the treatment time by causing faster melting of the slurry ice.
- Heat transfer from the surrounding (non-slurry-filled) tissue and by blood flow melts the slurry ice during this second stage.
- the biocompatible ice slurry has a first equilibration temperature of between about 4° C. to about ⁇ 30° C. and/or a second equilibration temperature of between about 2° C. to about ⁇ 30° C.
- equilibria temperature be achieved, for example, as follows: Using a slurry composition of hetastarch in lactated electrolyte (500 ml), saline (500 ml) and glycerol (100 ml), a slurry temperature of ⁇ 5° C. can be obtained. A single bolus injection of about 25 ml of the slurry composition into tissue with a starting temperature of 29° C.
- tissue temperature can rapidly bring the tissue temperature down to ⁇ 3.2° C. and maintain it below 0° C. for about 10-15 minutes;
- a slurry composition of hetastarch in lactated electrolyte (500 ml), saline (500 ml) and glycerol (50 ml) a slurry temperature of ⁇ 2.1° C. can be obtained.
- a first bolus injection of about 50 ml into tissue using a 15 gauge needle achieves a tissue temperature of about ⁇ 2° C. to ⁇ 1.3° C. The temperature can be maintained below 0° C. in the tissue for about 15 minutes.
- a second bolus injection of another 40-60 ml of slurry brings the tissue temperature down to about ⁇ 1.1° C. and maintains that temperature for greater than 15 minutes.
- the tissue temperature can be maintained below 0° C. for greater than 20 minutes.
- About 4-5 injections of the slurry composition can maintain cold temperatures below zero for 60 minutes to achieve hypoesthesia.
- Peripheral nerves subject to temperatures below zero for about 60 minutes will produce hypoethesia for several weeks (e.g., 6-8 weeks). Thus multiple cycles of slurry injections can be done to prolong the cooling effect with slurry injection.
- the rate of ice melting can be monitored in a given application and anatomic situation.
- ice is readily seen by medical ultrasound imaging that can be used to monitor the ice content, size and shape, and rate of ice melting from a target tissue.
- ice content in the treatment tissue can be monitored with ultrasound during and after infusion of the slurry.
- treatment can be greatly prolonged by providing repeated or continuous infusion of the slurry. Ultrasound guidance can be used to monitor ice content and adjust the repeated or continuous infusion of slurry accordingly.
- the location of the slurry placement can be monitored with the use of ultrasound.
- a targeted nerve can be monitored through the use of ultrasound to ensure correct placement of the slurry. This will allow precise delivery of the slurry and targeting of the desired nerve.
- methods that temporarily limit or eliminate local blood flow can be employed.
- mechanical forces can be applied to limit blood flow, including applying simple pressure after infusion of the slurry, or if appropriate, tourniquet application before during and after infusion of the slurry.
- Precooling the tissue prior to slurry injection can also induce vasoconstriction.
- Continuous external cooling after slurry injection can be employed to prolong the duration for which the slurry is effective in the tissue.
- Methods of the invention provide reversible inhibition of peripheral nerves. After administration of the slurry, inhibition can occur for up to about 5 months; for example, inhibition of peripheral nerves can be achieved for a period of minutes, days, weeks or months after a single administration of the slurry. Multiple cycles of administrations of the slurry can be provided to extend treatment as needed.
- the tissue can also be prechilled or precooled prior to infusion of the slurry to allow the tissue temperature to stay cooler for extended periods of time.
- the third stage after infusion of slurry occurs after the ice content has melted.
- the temperature of the target tissue is now able to return gradually to body temperature by the same processes that melted ice during the second stage—heat conduction, and heat convection via blood flow. It may take minutes or even hours for the target tissue to return to normal body temperature, depending again on the size, anatomy, and blood flow involved. Temperature in the target tissue increases in the third stage because all of the slurry ice has melted.
- Lipid-crystallization is one mechanism responsible for the temporary and prolonged loss of nerve conduction following cooling of nerves.
- the myelin sheath that surrounds nerve axons contains a high concentration of lipids.
- a primary function of the lipid-rich sheath is to isolate the axons, such that action potentials (i.e., nerve signals) can propagate.
- Disruption and/or loss of the myelin sheath after local cooling appear to follow a similar mechanism, with crystallization of the myelin lipids followed by stress and degradation.
- the myelin sheath is a cytoplasmic extension of Schwann cells, which are slow to repair this kind of injury.
- Prolonged (up to approximately 3 months or more) anesthesia, pain, or itch reduction is therefore an application for this invention; for example, a slurry can be used for prolonged nerve block after injection/infusion at many of the anatomic sites that are classically used for temporary nerve blocks using an anesthetic injection.
- Methods of the invention can reduce pain or itch or eliminate symptoms associated with neurological disorders such as neuropathic pain, diabetic neuropathy pain, trigeminal neuralgia, post-herpetic neuralgia, phantom limb pain, cancer related itch or pain, burn itch or pain, lichen sclerosus, scalp itch, nostalgia parastethica, atopic dermatitis, eczema, psoriasis, lichen planus, vulvar itch, vulvodynia, lichen simplex chornicus, prurigo nodularis, itch mediated by sensory nerves, peripheral neuropathy, peripheral nerve damage, post-thoracotomy pain, incisional pain, chest pain, coccydynia, lower back pain (with or without radiculopathy), superficial scars, neuromas, acute post-operation pain, lumbar facet joint syndrome and cutaneous pain disorder.
- neurological disorders such as neuropathic pain, diabetic neuropathy pain, trigeminal neural
- the cutaneous pain disorder includes, but is not limited to, reflex sympathetic dystrophy (RSD), phantom limb pain, neuroma, post herpetic neuralgia, headache, occipital neuralgia, tension headaches and vulvodynia.
- RSD reflex sympathetic dystrophy
- phantom limb pain neuroma
- post herpetic neuralgia headache
- occipital neuralgia tension headaches
- vulvodynia vulvodynia
- Methods of the invention can also be used to reduce or eliminate symptoms associated with pain disorders caused by peripheral neuropathy, peripheral nerve damage from metabolic, infectious, trauma, genetic or chemical process. Methods of the invention can also be used to reduce or eliminate cutaneous pain.
- Methods of the invention can also be used to reduce or eliminate symptoms associated with pain disorders caused by surgery, such as any surgery that makes an incision through the skin and induces pain.
- the slurry can be injected prior, during or after incision.
- a slurry can be used for inhibition of pain after thoracic surgery, by injection of about 3 cm 3 of slurry into the subcostal space.
- the final temperature is given by T final ⁇ 10 ⁇ Q iceresidual / ⁇ C.
- T final ⁇ 10 ⁇ Q iceresidual / ⁇ C.
- ⁇ C the value of ⁇ C for most soft tissues is close to 1 cal/° C.-cm 3 , such that T final ⁇ 10 ⁇ 7.6, or 2.4° C.
- Gradual warming of the ⁇ 6 cm 3 volume of slurry-tissue mix then occurs.
- a second or further injection of slurry can also be performed; the effectiveness of multiple cold cycles is typically greater than one cycle.
- Methods of the invention can also be used to reduce muscle spasms caused by aberrant nerve firing such as bladder or facial spasms.
- Methods of the invention can also be used to target motor nerves if prolonged paralysis of a motor nerve is desired.
- Methods of the invention can also be used to reduce, eliminate or alter functions controlled by the autonomic nervous system.
- the sympathetic nerve system controls hyperhidrosis through the sympathetic fibers that innervate the eccrine glands in the axilla.
- Methods of the invention can be used to target those autonomic nerve fibers to reduce hyperhidrosis.
- the solution comprising the slurry can be administered to the peripheral nerves of the subject by injection, infusion or tumescent pumping of the slurry into a nerve or nerves such as peripheral, subcutaneous or autonomic nerves of the subject by injection into a nerve or nerves selected from the group consisting of the cutaneous nerve, trigeminal nerve, ilioinguinal nerve, intercostal nerve, interscalene nerve, supraclavicular nerve, infraclavicular nerve, axillary nerve, pudental nerve, paravertebral nerve, transverse abdominis nerve, lumbar plexus nerve, femoral nerve and sciatic nerve.
- a nerve or nerves such as peripheral, subcutaneous or autonomic nerves of the subject by injection into a nerve or nerves selected from the group consisting of the cutaneous nerve, trigeminal nerve, ilioinguinal nerve, intercostal nerve, interscalene nerve, supraclavicular nerve, infraclavicular nerve, axillary nerve, pudental
- Methods of the invention can also reduce or eliminate pain associated with a nerve plexus (i.e., a group of intersecting nerves) including but not limited to the cervical plexus that serves the head, neck and shoulders; the brachial plexus that serves the chest, shoulders, arms and hands; the lumbar plexus that serves the back, abdomen, groin, thighs, knees, and calves; the sacral plexus that serves the pelvis, buttocks, genitals, thighs, calves, and feet; the celiac plexus (solar plexus) that serves internal organs; the coccygeal plexus that serves a small region over the coccyx; the Auerbach's plexus that serves the gastrointestinal tract; and Meissner's plexus (submucosal plexus) that serves the gastrointestinal tract.
- a nerve plexus i.e., a group of intersecting nerves
- a nerve plexus i.e.
- Methods of the invention can also be used for renal sympathetic denervation, which is an emerging therapy for the treatment of severe and/or resistant hypertension.
- Flowing the slurry through tissue allows cooling over a great distance from the infusion point, in particular through tissue structures with minimal resistance to fluid flow, e.g., along the perineural sheath of sensory or motor nerves.
- the solution can also be administered to any peripheral or cutaneous nerve that is accessible via a syringe needle percutaneously or through catheter via the circulatory system.
- the means for injecting the slurry can include additional features, such as, e.g., a sensor for providing temperature readings to allow monitoring of target tissue temperature.
- the means for injecting the slurry can optionally have the ability to retrieve the melted components of the slurry, while allowing the injection of new slurry, as depicted in FIG. 17 .
- the location of the injection can be verified, e.g., through MRI or x-ray imaging for example, when the slurry contains imaging agents known in the art.
- Pre-activation of nerves and/or verification of needle placement by electric or chemical stimulation can also performed in connection with methods of the invention.
- correct placement of the slurry can be facilitated by injecting anesthetic or electrical stimulation to produce sensation or anesthesia along the targeted nerve prior to injection of the slurry.
- the duration for which a slurry is administered can be determined by a physician or other qualified professional or technician and adjusted, as necessary, to suit observed effects of the treatment or as is needed, depending on the formulation of the slurry administered. It is well within the skill in the art to adjust the duration of treatment according to the methods described herein.
- Methods of the invention can also be used to treat urinary incontinence.
- urinary incontinence In a recent survey among women aged 25-84 in the United States an estimated 15% report experiencing stress incontinence and 13% report experiencing urge incontinence/“overactive bladder.” These two etiologies of incontinence are due to separate mechanisms, though both mechanisms may be experienced by a single patient.
- the smooth muscles of the bladder are innervated primarily by parasympathetic nerves; those of the bladder neck and urethra—the internal sphincter—are innervated by sympathetic nerves.
- the striated muscles of the external urethral sphincter (EUS) receive their primary innervation from somatic nerves.
- EUS external urethral sphincter
- Urgency incontinence is due to overactivity of the detrusor muscle.
- Therapies to treat urgency incontinence are primarily pharmacologic (e.g., Botulinum toxin) and are targeted toward decreasing neural input to the bladder muscle to prevent the frequent bladder spasms.
- pharmacologic e.g., Botulinum toxin
- another embodiment of the invention provides treatment of urgency incontinence by inhibiting neural input to the bladder.
- the treatment comprises an injectable therapy whereby the ice slurry is administered to, e.g., the neuromuscular junction, to inhibit neural input to the bladder.
- Heat capacity is an important component of the heat exchange between a slurry and a tissue.
- the first heat exchange to consider is that of the energy stored by the heat capacity of slurry and tissue.
- H energy density
- T temperature
- ⁇ density
- C specific heat capacity
- T m f s T s +(1 ⁇ f s ) T t
- the volume fraction of ice in a physiological slurry in this model is defined as I s , being the volume of ice per unit volume of slurry.
- I s the volume fraction of ice in the local slurry-tissue mix.
- I o is the total amount of ice available for melting, per unit volume of the slurry-tissue mix.
- ice in the slurry component of the slurry-tissue mix begins to melt, absorbing heat and cooling the slurry-tissue mix. Ice in the slurry-tissue mix melts until it is gone, or until an equilibrium temperature is reached, before the period of gradual warming by body heat exchange briefly discussed above.
- ice and liquid water can co-exist at equilibrium temperatures between 0° C. and 4° C.
- tissue there are numerous solutes that cause freezing point depression, such that ice and water co-exist over a somewhat lower temperature range, e.g., about ⁇ 8° C. to 0° C. in skin. Lipids in the tissue are in a liquid state at normal body temperature.
- lipids can crystallize.
- These two processes proceed in opposite directions (e.g., the water melts, the lipids crystallize) because lipid crystallization occurs at temperatures considerably higher than the freezing point of water.
- Most animal fats crystallize at between 10° C. and 15° C., depending on the length and saturation of the lipid chains in triglyceride molecules.
- Wax esters and free fatty acids crystallize at similar temperatures.
- Polar lipids crystallize at lower temperatures, for example the phospholipids of cell membranes can remain somewhat fluid even well below 0° C.
- Injected physiological slurries are effective to inhibit pain or itch by affecting nerve myelin sheath lipids. Lipids of the sheath crystallize well above 0° C. Effective treatment depends on variables including the starting tissue temperature T t , the ice content of slurry I s , the amount and speed of slurry injected to achieve an adequate slurry fraction f s in the slurry-tissue mix, the target lipid content of the tissue L t , its crystallization temperature T c , and the time for which some ice remains in the slurry-tissue mix.
- Enthalpy of fusion also called heat of fusion
- heat of fusion describes how much thermal energy is absorbed (endothermic) or released (exothermic) due to changing from solid to liquid state.
- the melting of ice is an endothermic transition requiring a large amount of thermal energy.
- the heat of fusion is 80 cal/gm.
- the density of ice at 0° C. is 0.92, such that the volumetric heat of fusion, H ice (the heat energy needed to melt a volume of ice) is:
- Typical values as mentioned above for f s range from about 0.2 to 0.8, and the ice content of physiological slurry can be up to about 50% (I s ⁇ 0.5).
- the range (without limitation) for Q icetotal in the slurry-tissue mix is therefore about 7 to 30 cal/cm 3 .
- the heat of fusion for animal fat lipids ranges from about 30-50 cal/gm ( Cooling Technology in the Food Industry ; Taylor and Francis, 1976).
- the density of lipids range from about 0.8-0.9 gm/cm 3 (e.g., palmitic triglyceride in solid phase is 0.85 gm/cm 3 ).
- the latent heat per unit volume for crystallization of lipids is about:
- H lipid 34 cal/cm 3 .
- the latent heat for crystallization of lipids is less than half of that for melting of ice. Cooling of the slurry-tissue mix proceeds by some ice melting, until the temperature reaches about 10° C., the temperature necessary for lipid crystallization to begin.
- the thermal energy from consumed by dropping the temperature of the slurry-tissue mix to about 10° C. is given by:
- the lipid content of the slurry-tissue mix is therefore another important factor. Defining the lipid content of the tissue as f tflip , the lipid content of the slurry-tissue mix is:
- f mlip (1 ⁇ f s ) f tlip .
- f tlip depends on tissue type.
- the energy per unit volume of the slurry-tissue mix that is produced by crystallizating all of the lipid present, is:
- f lipxtal ( Q icetotal ⁇ Q to10C )/ Q liptotal
- the lowest temperature reached is determined by heat exchange between the residual ice melting, and the heat capacity of the slurry-tissue mix.
- the lowest temperature T final can therefore be estimated by equating the latent heat per unit volume absorbed by melting of the residual ice, with the heat associated with heat capacity of the temperature drop below about 10° C.
- the temperature drop to T final due to residual ice melting can be estimated by:
- the local heat exchanges modeled above occur over a time scale of seconds because the slurry is intimately in contact with tissue, by mixing flowing and/or dissecting through the soft tissue during interstitial injection.
- the temperature of the slurry-tissue mix settles at about T final , then gradually warms due to conduction and convection.
- the rate of gradual warming depends therefore on the rates of conduction and convection. In the absence of blood flow (convection), warming by conduction involves a minimum characteristic time, proportional to the square of the diameter of the local slurry-tissue mix.
- the time in seconds for substantial warming of a region by conduction is approximately equal to the square of the diameter in millimeters.
- a 10 mm diameter slurry-tissue mix would typically takes about 100 seconds for substantial warming
- a 30 mm diameter slurry-tissue mix would typically takes about 900 seconds (i.e., 15 minutes) for substantial warming by conduction.
- some ice may remain even after this estimated period of substantial warming.
- the model presented here is illustrative, not exact. Direct measurement of slurry and tissue temperatures can be performed. As shown below, such measurements are generally consistent with this approximate model.
- a 6% hetastarch lactated Ringer's slurry (i.e., hetastach (500 ml), saline (500 ml) and glycerol (50 ml), blended together) was injected on top of the sciatic nerve of a male rat weighing about 250-271 g.
- the procedure was conducted as follows: The rat was placed under general anesthesia using inhaled isoflurane and oxygen. The sciatic nerve was exposed via surgical dissection ( FIG. 3 ). A starting slurry temperature of ⁇ 3.2° C. to ⁇ 2.7° C. was obtained and maintained throughout the experiment. For each of five injections, 5 ml of slurry was injected on top of the sciatic nerve. A thermocouple placed under the sciatic nerve was used to record tissue temperature ( FIG. 4 ).
- the 6% hetastarch lactated Ringer's slurry can maintain nerve tissue temperature below 0° C. for an average of 5 minutes and the tissue temperature was maintained as long as ice was present in the slurry ( FIGS. 5, 6 and 7 ).
- the nerve block is predicted to last days, weeks or months. When the ice turned to liquid, the tissue temperature rapidly rose above zero. Precooling the tissue around the nerve made the slurry last longer, as melting of the ice occurred at a slower rate ( FIG. 6 ).
- the efficacy of cold therapy in large motor and sensory nerve can be demonstrated in a rodent model by assessing nerve tissue staining and conducting assays to measure motor and sensory function following injection of cold slurry.
- Sensory experiments were conducted on 12 adult male rats having a mass between 250 grams and 350 grams. The rats were habituated to the testing environment, labeled 1-12, and randomized into 2 groups of 6 rats each. Baseline sensory testing was performed 1 day prior to the procedure.
- CCI chronic constriction injury
- the slurry injected into the six rats in the experimental group consisted of 5% glycerol (by weight) in normal saline, plus a 5% glycerol spike (by weight) prior to injection.
- 10 cc of slurry was injected around the sciatic nerve in each rat.
- a thermocouple was placed beside the nerve to record the temperature.
- the mean temperature of the slurry overlying the sciatic nerve at the time of injection was about ⁇ 1.1° C.
- the temperature reached +5° C., the area was blotted with sterile gauze and an additional 10 cc of slurry was injected around the sciatic nerve again.
- the tissue temperature in the injection site reached +5° C. in about 5 minutes on average.
- FIG. 10 depicts the thermal hindpaw withdrawal latencies of responder rats showing longer response times to a heat exposure in rats at 20, 25, and 42 days post-slurry-injection. Longer response times indicate less pain from thermal stimuli indicating that slurry reduces thermal pain.
- FIG. 11 depicts testing results by comparing differences in thermal withdrawal latencies of responder rats with normalization to internal control. A positive value indicates that the left paw withdraws quicker to heat pain than the right. Declining differences in latency between the left paw and the right paw can be seen after slurry injection indicating that slurry reduces thermal pain.
- NS is an abbreviation for “normal saline” (0.90% grams NaCl per ml H 2 O).
- hetastarch is another term for “hydroxyethyl starch”, a nonionic starch derivative.
- HEXTEND® 6% hetastarch lactated electrolyte injection having an average molecular weight of 670,000 Daltons and available from Hospira, Inc. of Lake Forest, Ill. was used for the experiment conducted herein.
- LR is an abbreviation for lactated Ringer's solution Percentages of glycerol are expressed in terms of g/ml.
- Hetastarch + 5% glycerol R thigh sciatic ⁇ 4.3 7-10 Hetastarch + 5% glycerol R thigh sciatic ⁇ 4.3 7-10 9.
- LR + 10% glycerol R thigh sciatic ⁇ 3.0 7-10 10.
- LR + 10% glycerol R thigh sciatic ⁇ 3.1 7-10 Ice flakes in cold R thigh sciatic ⁇ 0.2 7-10 hetastarch ⁇ glycerol 12. Ice flakes in cold R thigh sciatic 0.0 7-10 hetastarch ⁇ glycerol
- FIG. 12 the effect of increasing glycerol concentrations (in normal saline) on slurry temperatures are depicted. Increasing the amount of glycerol in the slurry led to dramatic drop in slurry temperature.
- the safety and tolerability limit of lowest tolerable slurry temperature was tested with the injection s of slurries shown in Table 5. All of the animals tolerated the injection with no sign of infection, ulceration, necrosis or side effects up to one week after the injection, at which time the animals were sacrificed. No abnormalities were noted at time of necropsy.
- tattoo ink black pigment
- a slurry composed of normal saline and 20% glycerol.
- This slurry was injected in a Sprague-Dawley rat, into the anatomic pocket containing the sciatic nerve.
- the rat was sacrificed, and the skin overlying the anatomic pocket containing the sciatic nerve was then dissected to confirm the placement of the slurry (visible due to the tattoo ink) adjacent to the sciatic nerve.
- This image demonstrates the feasibility of delivering slurry around the sciatic nerve by blind injection through the skin.
- Thermal withdrawal latencies represent the amount of time it takes a rat to withdraw its hindpaw from an infrared heat source, thus a higher value means a higher threshold for pain and a lower value means that the rat has increased sensitivity to pain.
- All rats received chronic constriction injury (CCI) to model chronic neuropathic pain.
- CCI chronic constriction injury
- the common sciatic nerve was exposed using blunt dissection through the biceps femoris and was separated from adjacent tissue.
- a 4-0 chromic gut suture was loosely tied around the nerve at 2 points about 1 mm apart from each other.
- the desired degree of constriction retards, but does not arrest, circulation through the superficial epineurial vasculature.
- Sensory testing was repeated on the rats 6 days post-CCI to demonstrate efficacy of the procedure. All rats had the sciatic nerve exposed using blunt dissection 1 week post-CCI.
- the slurry injected into the rats in the experimental group consisted of 10% glycerol (by weight) in normal saline, and had a mean temperature of ⁇ 3.9° C.
- a thermocouple was placed beside the nerve to record the temperature. Initially, 5 cc of slurry was injected onto the nerve in each rat. Subsequently, using a syringe smaller than the delivery syringe, slurry was continuously removed from the site as it melted and was replaced with new ice slurry. A 15 minute cooling duration of the nerve was ensured, defined as a temperature of less than +5° C. at the site of the nerve. A sample of the slurry was removed from the container and allowed to warm to room temperature. This room temperature solution of identical composition to the slurry was injected into control (room temperature slurry) rats.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/505,039 US20170274078A1 (en) | 2014-08-28 | 2015-08-27 | Compositions and methods for treatment of neurological disorders |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462042979P | 2014-08-28 | 2014-08-28 | |
US201562121329P | 2015-02-26 | 2015-02-26 | |
US201562121472P | 2015-02-26 | 2015-02-26 | |
PCT/US2015/047292 WO2016033380A1 (en) | 2014-08-28 | 2015-08-27 | Compositions and methods for treatment of neurological disorders |
US15/505,039 US20170274078A1 (en) | 2014-08-28 | 2015-08-27 | Compositions and methods for treatment of neurological disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/047292 A-371-Of-International WO2016033380A1 (en) | 2014-08-28 | 2015-08-27 | Compositions and methods for treatment of neurological disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/236,567 Continuation US11826427B2 (en) | 2014-08-28 | 2021-04-21 | Compositions and methods for treatment of neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170274078A1 true US20170274078A1 (en) | 2017-09-28 |
Family
ID=55400611
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/505,042 Abandoned US20170274011A1 (en) | 2014-08-28 | 2015-08-27 | Injectable slurries and methods of manufacturing and using the same |
US15/505,039 Abandoned US20170274078A1 (en) | 2014-08-28 | 2015-08-27 | Compositions and methods for treatment of neurological disorders |
US17/188,359 Active US11938188B2 (en) | 2014-08-28 | 2021-03-01 | Injectable slurries and methods of manufacturing and using the same |
US17/236,567 Active 2035-11-04 US11826427B2 (en) | 2014-08-28 | 2021-04-21 | Compositions and methods for treatment of neurological disorders |
US18/487,887 Active US11964017B2 (en) | 2014-08-28 | 2023-10-16 | Compositions and methods for treatment of neurological disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/505,042 Abandoned US20170274011A1 (en) | 2014-08-28 | 2015-08-27 | Injectable slurries and methods of manufacturing and using the same |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/188,359 Active US11938188B2 (en) | 2014-08-28 | 2021-03-01 | Injectable slurries and methods of manufacturing and using the same |
US17/236,567 Active 2035-11-04 US11826427B2 (en) | 2014-08-28 | 2021-04-21 | Compositions and methods for treatment of neurological disorders |
US18/487,887 Active US11964017B2 (en) | 2014-08-28 | 2023-10-16 | Compositions and methods for treatment of neurological disorders |
Country Status (16)
Country | Link |
---|---|
US (5) | US20170274011A1 (ja) |
EP (4) | EP3185876B1 (ja) |
JP (6) | JP6707525B2 (ja) |
KR (2) | KR102507789B1 (ja) |
CN (4) | CN113813222A (ja) |
AU (4) | AU2015308790B2 (ja) |
BR (2) | BR112017003111B1 (ja) |
CA (2) | CA2958769A1 (ja) |
DK (2) | DK3185876T3 (ja) |
ES (1) | ES2898097T3 (ja) |
MX (3) | MX2017002274A (ja) |
PL (1) | PL3185854T3 (ja) |
PT (1) | PT3185854T (ja) |
SG (4) | SG11201701505RA (ja) |
WO (2) | WO2016033380A1 (ja) |
ZA (3) | ZA201701048B (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200046552A1 (en) * | 2017-03-01 | 2020-02-13 | Miraki Innovation Think Tank Llc | Cryotherapies |
WO2021016457A1 (en) | 2019-07-24 | 2021-01-28 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
WO2021151019A1 (en) | 2020-01-23 | 2021-07-29 | The General Hospital Corporation | Novel method of enhanced drug delivery to the nervous system |
US20210369612A1 (en) * | 2018-10-04 | 2021-12-02 | Miraki Innovation Think Tank Llc | Slurry and solution compositions |
WO2022016015A1 (en) * | 2020-07-15 | 2022-01-20 | Lyotip, Inc. | Formulations for tetracaine and lidocaine |
US11241541B2 (en) | 2017-08-21 | 2022-02-08 | Miraki Innovation Think Tank Llc | Cold slurry syringe |
US11241330B1 (en) | 2021-04-02 | 2022-02-08 | Brixton Biosciences, Inc. | Apparatus for creation of injectable slurry |
US11324673B2 (en) | 2016-11-18 | 2022-05-10 | Miraki Innovation Think Tank Llc | Cosmetic appearance of skin |
US11439532B2 (en) | 2017-04-05 | 2022-09-13 | Miraki Innovation Think Tank Llc | Point of delivery cold slurry generation |
US11446178B2 (en) | 2017-04-05 | 2022-09-20 | Miraki Innovation Think Tank Llc | Cold slurry containment |
US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
WO2022261494A1 (en) * | 2021-06-11 | 2022-12-15 | Brixton Biosciences, Inc. | Methods of creating a slurry using liposome emulsions |
US11564830B2 (en) | 2016-02-26 | 2023-01-31 | The General Hospital Corporation | Medical ice slurry production and delivery systems and methods |
US11819451B2 (en) | 2020-07-10 | 2023-11-21 | C° Change Surgical Llc | Injectable slush feed supply |
US11826427B2 (en) | 2014-08-28 | 2023-11-28 | The General Hospital Corporation | Compositions and methods for treatment of neurological disorders |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9980765B2 (en) | 2010-02-15 | 2018-05-29 | The General Hospital Corporation | Methods and devices for selective disruption of visceral fat by controlled cooling |
ES2910440T3 (es) | 2010-11-16 | 2022-05-12 | Tva Medical Inc | Dispositivos para formar una fístula |
US10588691B2 (en) | 2012-09-12 | 2020-03-17 | Relievant Medsystems, Inc. | Radiofrequency ablation of tissue within a vertebral body |
US9486276B2 (en) | 2012-10-11 | 2016-11-08 | Tva Medical, Inc. | Devices and methods for fistula formation |
WO2014071161A1 (en) | 2012-11-05 | 2014-05-08 | Relievant Medsystems, Inc. | System and methods for creating curved paths through bone and modulating nerves within the bone |
JP6527134B2 (ja) | 2013-03-14 | 2019-06-05 | ティーブイエー メディカル, インコーポレイテッド | 瘻孔作成装置およびそのための方法 |
US9724151B2 (en) | 2013-08-08 | 2017-08-08 | Relievant Medsystems, Inc. | Modulating nerves within bone using bone fasteners |
MX2016007411A (es) | 2013-12-05 | 2017-01-09 | Rfemb Holdings Llc | Presentacion de antigeno de cancer mejorado a celulas que presentan por la descomposicion electrica de membrana por radiofrecuencia (rf-rmb) como un mecanismo adyuvante para la inmunoterapia. |
US10695534B2 (en) | 2014-03-14 | 2020-06-30 | Tva Medical, Inc. | Fistula formation devices and methods therefor |
US10646666B2 (en) | 2014-08-27 | 2020-05-12 | Tva Medical, Inc. | Cryolipolysis devices and methods therefor |
US11534335B2 (en) | 2014-10-01 | 2022-12-27 | Cryosa, Inc. | Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues |
US10603040B1 (en) | 2015-02-09 | 2020-03-31 | Tva Medical, Inc. | Methods for treating hypertension and reducing blood pressure with formation of fistula |
US11161156B2 (en) * | 2015-10-27 | 2021-11-02 | Hamilton Sundstrand Corporation | Powder monitoring |
CA3011460A1 (en) | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
WO2017124062A1 (en) | 2016-01-15 | 2017-07-20 | Tva Medical, Inc. | Devices and methods for forming a fistula |
US10874422B2 (en) | 2016-01-15 | 2020-12-29 | Tva Medical, Inc. | Systems and methods for increasing blood flow |
EP4299099A3 (en) | 2016-01-15 | 2024-04-03 | TVA Medical, Inc. | Devices for advancing a wire |
AU2017331090C1 (en) | 2016-09-25 | 2023-08-03 | Tva Medical, Inc. | Vascular stent devices and methods |
KR20200020657A (ko) | 2016-11-02 | 2020-02-26 | 크리스토퍼 제이 피 벨리스 | 슬러리 생성을 위한 디바이스 및 방법 |
EP3723658A4 (en) * | 2017-12-11 | 2021-09-08 | Saban Ventures Pty Limited | SUSPENSION CLEANING |
AU2019355657A1 (en) * | 2018-10-04 | 2021-05-13 | Miraki Innovation Think Tank Llc | Methods of treating subcutaneous fat layers |
WO2020077090A1 (en) * | 2018-10-10 | 2020-04-16 | Miraki Innovation Think Tank Llc | Systems and methods of generating slurry for injection |
SG11202103516SA (en) * | 2018-10-10 | 2021-05-28 | Miraki Innovation Think Tank Llc | Systems and methods for generating slurry |
WO2020077072A1 (en) * | 2018-10-12 | 2020-04-16 | Miraki Innovation Think Tank Llc | Cold solution for fat reduction |
CN109800472B (zh) * | 2018-12-26 | 2022-09-27 | 哈尔滨工程大学 | 一种冰桨接触过程中桨叶表面瞬时冰载压力分布计算方法 |
US11576812B2 (en) | 2019-04-25 | 2023-02-14 | Carlos Wambier | Methods for reducing body fat in a subject |
EP4027912A4 (en) | 2019-09-12 | 2023-08-16 | Relievant Medsystems, Inc. | TISSUE MODULATION SYSTEMS AND METHODS |
JP2022549499A (ja) | 2019-09-26 | 2022-11-25 | ミラキ イノベーション シンク タンク エルエルシー | 小型の体内で制御可能な医療機器 |
EP4081746A4 (en) * | 2019-12-24 | 2024-01-17 | Miraki Innovation Think Tank Llc | SUBSTANTIALLY SOLID SOLUTION, SYSTEMS AND METHODS FOR PRODUCING A SUBSTANTIALLY SOLID SOLUTION AND METHODS FOR ADMINISTRATION THEREOF |
US20230046673A1 (en) * | 2019-12-26 | 2023-02-16 | Miraki Innovation Think Tank Llc | Treatment of obstructive sleep apnea |
US20230028322A1 (en) * | 2019-12-31 | 2023-01-26 | Miraki Innovation Think Tank Llc | Cold solution for inducing therapeutic hypothermia |
WO2021195582A1 (en) * | 2020-03-27 | 2021-09-30 | James Anthony Stefater, Iii | Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry |
US20220071900A1 (en) * | 2020-09-08 | 2022-03-10 | Brixton Biosciences, Inc. | Systems and methods for preparing and transporting an injectable slurry |
US20220087250A1 (en) * | 2020-09-24 | 2022-03-24 | Everest Medical Innovation GmbH | Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery |
US11490925B1 (en) | 2021-06-09 | 2022-11-08 | Mohammed A. Alsufyani | Combination ultrasound transducer and fat injecting cannula |
WO2023064528A1 (en) * | 2021-10-14 | 2023-04-20 | The General Hospital Corporation | Compositions and methods for treatment of obstructive sleep apnea |
WO2023150739A2 (en) * | 2022-02-07 | 2023-08-10 | Moskovitz Martin J | Cryo-surgical device and materials and method of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4986079A (en) * | 1988-08-12 | 1991-01-22 | Hitachi, Ltd. | Apparatus and method of generating coldness |
US20020107199A1 (en) * | 2000-12-05 | 2002-08-08 | Allergan Sales, Inc. | Methods of administering botulinum toxin |
US6430957B1 (en) * | 1999-05-25 | 2002-08-13 | Agency Of Industrial Science & Technology Ministry Of International Trade & Industry | Method and apparatus for thermal transportation using polyvinyl alcohol |
US20130190744A1 (en) * | 2010-02-15 | 2013-07-25 | The General Hospital Corporation | Methods and devices for selective disruption of visceral fat by controlled cooling |
Family Cites Families (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1256372A (en) | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
US5143063A (en) | 1988-02-09 | 1992-09-01 | Fellner Donald G | Method of removing adipose tissue from the body |
JP2792702B2 (ja) | 1988-10-05 | 1998-09-03 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | 乾燥時に改善された安定性を示すリポソームの調製方法 |
US5005364A (en) | 1990-02-07 | 1991-04-09 | Nelson William R | Apparatus for and method of making and delivering slush ice |
ES2103376T3 (es) | 1991-07-05 | 1997-09-16 | Nycomed Imaging As | Perfeccionamientos introducidos en los agentes de contraste. |
US5507790A (en) | 1994-03-21 | 1996-04-16 | Weiss; William V. | Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism |
US5769879A (en) | 1995-06-07 | 1998-06-23 | Medical Contouring Corporation | Microwave applicator and method of operation |
US6126657A (en) | 1996-02-23 | 2000-10-03 | Somnus Medical Technologies, Inc. | Apparatus for treatment of air way obstructions |
US6464697B1 (en) | 1998-02-19 | 2002-10-15 | Curon Medical, Inc. | Stomach and adjoining tissue regions in the esophagus |
US6467953B1 (en) | 1999-03-30 | 2002-10-22 | Medical Solutions, Inc. | Method and apparatus for monitoring temperature of intravenously delivered fluids and other medical items |
US7892229B2 (en) | 2003-01-18 | 2011-02-22 | Tsunami Medtech, Llc | Medical instruments and techniques for treating pulmonary disorders |
US6126684A (en) | 1998-04-21 | 2000-10-03 | The Regents Of The University Of California | Indwelling heat exchange catheter and method of using same |
US6546932B1 (en) | 1999-04-05 | 2003-04-15 | Cryocath Technologies Inc. | Cryogenic method and apparatus for promoting angiogenesis |
DE60014093T2 (de) | 1999-07-16 | 2005-02-03 | Alza Corp., Mountain View | Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden |
US6596333B1 (en) | 1999-07-21 | 2003-07-22 | Nestec S.A. | Process for producing aerated frozen products |
US6962601B2 (en) | 1999-08-02 | 2005-11-08 | University Of Chicago Office Of Technology Transfer | Method for inducing hypothermia |
US6244052B1 (en) * | 1999-08-02 | 2001-06-12 | The University Of Chicago | Method and apparatus for producing phase change ice particulate perfluorocarbon slurries |
US7422601B2 (en) * | 1999-08-02 | 2008-09-09 | University Of Chicago Office Of Technology Transfer | Method for inducing hypothermia |
US6413444B1 (en) | 1999-08-02 | 2002-07-02 | The University Of Chicago | Methods and apparatus for producing phase change ice particulate saline slurries |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US7306591B2 (en) | 2000-10-02 | 2007-12-11 | Novasys Medical, Inc. | Apparatus and methods for treating female urinary incontinence |
US7897141B2 (en) | 2002-04-01 | 2011-03-01 | Drexel University | Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof |
US20030032996A1 (en) * | 2001-08-08 | 2003-02-13 | Hallman Arlan Jay | Cryogenic massage tube and compress |
US6709431B2 (en) | 2001-12-18 | 2004-03-23 | Scimed Life Systems, Inc. | Cryo-temperature monitoring |
IL163689A0 (en) * | 2002-02-26 | 2005-12-18 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound zd1839 |
AU2003220311B2 (en) | 2002-03-15 | 2009-01-29 | The General Hospital Corporation | Methods and devices for selective disruption of fatty tissue by controlled cooling |
US8840608B2 (en) | 2002-03-15 | 2014-09-23 | The General Hospital Corporation | Methods and devices for selective disruption of fatty tissue by controlled cooling |
US6858025B2 (en) | 2002-08-06 | 2005-02-22 | Medically Advanced Designs, Llc | Cryo-surgical apparatus and method of use |
US7211104B2 (en) | 2002-10-08 | 2007-05-01 | Vital Wear, Inc. | Contrast therapy system and method |
US7083612B2 (en) | 2003-01-15 | 2006-08-01 | Cryodynamics, Llc | Cryotherapy system |
US20040258760A1 (en) | 2003-03-20 | 2004-12-23 | Wheatley Margaret A. | Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production |
JP2006521184A (ja) | 2003-03-26 | 2006-09-21 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 熱的外科手術及び組成物 |
US20060161232A1 (en) | 2005-01-18 | 2006-07-20 | Kasza, Oras and Son to The University of Chicago | Phase-change particulate ice slurry coolant medical delivery tubing and insertion devices |
US7713266B2 (en) | 2005-05-20 | 2010-05-11 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
US7850683B2 (en) | 2005-05-20 | 2010-12-14 | Myoscience, Inc. | Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat) |
US20090326621A1 (en) | 2005-05-24 | 2009-12-31 | Rizk El-Galley | Surgical delivery devices and methods |
US7389653B2 (en) * | 2005-09-15 | 2008-06-24 | The University Of Chicago | Medical ice slurry production device |
US20070093697A1 (en) | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
US7854754B2 (en) | 2006-02-22 | 2010-12-21 | Zeltiq Aesthetics, Inc. | Cooling device for removing heat from subcutaneous lipid-rich cells |
GB0615287D0 (en) | 2006-08-01 | 2006-09-06 | Ares Trading Sa | Integral membrane protein |
US8192474B2 (en) | 2006-09-26 | 2012-06-05 | Zeltiq Aesthetics, Inc. | Tissue treatment methods |
JP2010508130A (ja) | 2006-10-31 | 2010-03-18 | ゼルティック エステティックス インコーポレイテッド | 皮下高脂質細胞または皮下高脂質組織を冷却する方法およびその装置 |
US9254162B2 (en) | 2006-12-21 | 2016-02-09 | Myoscience, Inc. | Dermal and transdermal cryogenic microprobe systems |
US20080247957A1 (en) | 2007-02-16 | 2008-10-09 | Drexel University | Advanced drug delivery strategy and platform for minimally-invasive treatment of liver cancer |
WO2008150871A1 (en) | 2007-05-30 | 2008-12-11 | Critical Care Innovations, Inc. | Process and device for selectively treating interstitial tissue |
US20090028797A1 (en) | 2007-06-14 | 2009-01-29 | Drexel University | Novel polymeric ultrasound contrast agent and methods of making thereof |
WO2009009540A1 (en) | 2007-07-09 | 2009-01-15 | Velomedix, Inc. | Hypothermia devices and methods |
US8523927B2 (en) | 2007-07-13 | 2013-09-03 | Zeltiq Aesthetics, Inc. | System for treating lipid-rich regions |
EP2944694B1 (en) | 2007-10-12 | 2018-07-11 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin | Method for opening tight junctions |
US8298216B2 (en) | 2007-11-14 | 2012-10-30 | Myoscience, Inc. | Pain management using cryogenic remodeling |
US8563515B2 (en) | 2007-11-19 | 2013-10-22 | The Regents Of The University Of Colorado, A Body Corporate | Tight junction protein modulators and uses thereof |
US20090234325A1 (en) | 2008-03-17 | 2009-09-17 | Allan Rozenberg | Methods and devices for non-invasive cerebral and systemic cooling |
EP2265227A4 (en) | 2008-04-01 | 2013-08-07 | Gen Hospital Corp | METHOD AND APPARATUS FOR COOLING BIOLOGICAL TISSUE |
US8505315B2 (en) * | 2008-04-15 | 2013-08-13 | Uchicago Argonne, Llc | Enhanced integrated operation blender based sterile medical ice slurry production device |
US7874167B2 (en) | 2008-06-06 | 2011-01-25 | C Change Surgical Llc | Method and apparatus for producing slush for surgical use |
WO2010017556A1 (en) | 2008-08-08 | 2010-02-11 | Palomar Medical Technologies, Inc | Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue |
US8849441B2 (en) * | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US8603073B2 (en) | 2008-12-17 | 2013-12-10 | Zeltiq Aesthetics, Inc. | Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells |
US8480664B2 (en) | 2009-01-15 | 2013-07-09 | Boston Scientific Scimed, Inc. | Controlling depth of cryoablation |
US8608696B1 (en) | 2009-02-24 | 2013-12-17 | North Carolina State University | Rapid fluid cooling devices and methods for cooling fluids |
US20110009748A1 (en) | 2009-06-11 | 2011-01-13 | Galil Medical Ltd. | Transperineal prostate biopsy system and methods |
US20130011332A1 (en) | 2009-09-15 | 2013-01-10 | Searete Llc, | Frozen Compositions and Methods for Piercing a Substrate |
US20140200511A1 (en) * | 2009-10-30 | 2014-07-17 | Searete Llc | Systems, devices, and methods for making or administering frozen particles |
WO2012027641A2 (en) | 2010-08-26 | 2012-03-01 | Cryomedix, Llc | Cryoablation balloon catheter and related method |
US9095320B2 (en) | 2010-09-27 | 2015-08-04 | CyroMedix, LLC | Cryo-induced renal neuromodulation devices and methods |
US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US20120130458A1 (en) | 2010-10-26 | 2012-05-24 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
CA2820731A1 (en) | 2010-12-13 | 2012-06-21 | Myoscience, Inc. | Method for reducing hyperdynamic facial wrinkles |
GB2485864B (en) | 2011-07-14 | 2013-05-29 | Ide Technologies Ltd | Vacuum ice maker (vim) with an integrated water vapor depostion process |
CA2825033C (en) | 2011-02-01 | 2018-08-28 | Channel Medsystems, Inc. | Methods and apparatus for cryogenic treatment of a body cavity or lumen |
US9237924B2 (en) | 2011-06-14 | 2016-01-19 | Aerin Medical, Inc. | Methods and devices to treat nasal airways |
EP2561886A1 (en) | 2011-08-23 | 2013-02-27 | Forschungsverbund Berlin e.V. | Peptide adjuvant for improved peripheral analgesia |
JP6133308B2 (ja) | 2011-10-21 | 2017-05-24 | セレーター ファーマシューティカルズ インコーポレイテッド | 凍結乾燥リポソーム |
CN104394813B (zh) | 2011-11-16 | 2018-11-09 | 通用医疗公司 | 用于低温处理皮肤组织的方法和装置 |
BR112014017175A8 (pt) | 2012-01-13 | 2017-07-04 | Myoscience Inc | proteção de pele para remodelagem criogênica subdérmica para tratamentos cosméticos e outros |
EP2854681A4 (en) | 2012-06-01 | 2016-02-17 | Cibiem Inc | PERCUTANEOUS METHODS AND DEVICES FOR CAROTIDE BODY ABLATION |
JP6168644B2 (ja) | 2012-07-12 | 2017-07-26 | 国立大学法人弘前大学 | 氷スラリー製造装置および氷スラリー製造方法 |
US9844460B2 (en) | 2013-03-14 | 2017-12-19 | Zeltiq Aesthetics, Inc. | Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same |
US9033966B2 (en) | 2013-03-15 | 2015-05-19 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US9023022B2 (en) | 2013-03-15 | 2015-05-05 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device having release instrument |
US9131975B2 (en) | 2013-03-15 | 2015-09-15 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US20140350536A1 (en) | 2013-03-15 | 2014-11-27 | Myoscience, Inc. | Cryogenic Blunt Dissection Methods and Devices |
US9610112B2 (en) | 2013-03-15 | 2017-04-04 | Myoscience, Inc. | Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis |
US9023023B2 (en) | 2013-03-15 | 2015-05-05 | Warsaw Orthopedic, Inc. | Nerve and soft tissue ablation device |
US9295512B2 (en) | 2013-03-15 | 2016-03-29 | Myoscience, Inc. | Methods and devices for pain management |
EP3030305B1 (en) | 2013-08-05 | 2020-07-01 | Yue Wu | System for producing and delivering airless medical ice slurry to induce hypothermia |
WO2015048806A2 (en) | 2013-09-30 | 2015-04-02 | Nidus Medical, Llc | Apparatus and methods for treating rhinitis |
US10660688B2 (en) | 2014-05-12 | 2020-05-26 | Gary Kalser | Cryotherapy device with cryoprotection and methods for performing cryotherapy with cryoprotection |
US9763743B2 (en) | 2014-07-25 | 2017-09-19 | Arrinex, Inc. | Apparatus and method for treating rhinitis |
US10646666B2 (en) | 2014-08-27 | 2020-05-12 | Tva Medical, Inc. | Cryolipolysis devices and methods therefor |
CN113813222A (zh) | 2014-08-28 | 2021-12-21 | 通用医疗公司 | 治疗神经疾病的组合物和方法 |
US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US9549843B2 (en) | 2014-11-30 | 2017-01-24 | C° Change Surgical Llc | Production of well-mixed surgical slush |
CN204468406U (zh) | 2015-02-05 | 2015-07-15 | 张淑华 | 一种新型便携式冷敷装置 |
WO2016145452A1 (en) | 2015-03-12 | 2016-09-15 | Myoscience, Inc. | Methods and systems for preventing neuroma formations |
US20160317346A1 (en) | 2015-04-28 | 2016-11-03 | Zeltiq Aesthetics, Inc. | Systems and methods for monitoring cooling of skin and tissue to identify freeze events |
US10524956B2 (en) | 2016-01-07 | 2020-01-07 | Zeltiq Aesthetics, Inc. | Temperature-dependent adhesion between applicator and skin during cooling of tissue |
SG10201913504XA (en) | 2016-02-26 | 2020-03-30 | Massachusetts Gen Hospital | Medical ice slurry production and delivery systems and methods |
CN105640642B (zh) | 2016-04-07 | 2018-01-12 | 上海导向医疗系统有限公司 | 带扩张球囊的内冷却微波消融针 |
US11382790B2 (en) | 2016-05-10 | 2022-07-12 | Zeltiq Aesthetics, Inc. | Skin freezing systems for treating acne and skin conditions |
DE102016115387B3 (de) | 2016-08-18 | 2018-02-01 | Cardiolectra GmbH | Medizinisches Gerät zur Denervierung renaler perivaskulärer Nerven |
EP3506846A4 (en) | 2016-08-30 | 2021-01-06 | The General Hospital Corporation | CRYOTHERAPY AND CRYOABLATION SYSTEMS AND METHODS OF TISSUE TREATMENT |
KR20200020657A (ko) | 2016-11-02 | 2020-02-26 | 크리스토퍼 제이 피 벨리스 | 슬러리 생성을 위한 디바이스 및 방법 |
KR101905830B1 (ko) | 2016-11-15 | 2018-10-08 | 울산과학기술원 | 국부 냉각 마취 장치, 국부 냉각 마취 장치의 제어 방법 및 국부 냉각 마취 장치의 냉각 온도 조절기 |
US11324673B2 (en) | 2016-11-18 | 2022-05-10 | Miraki Innovation Think Tank Llc | Cosmetic appearance of skin |
ES2936210T3 (es) | 2017-02-04 | 2023-03-15 | Vessi Medical Ltd | Control de flujo de dispositivo de crioterapia |
US9980076B1 (en) | 2017-02-21 | 2018-05-22 | At&T Intellectual Property I, L.P. | Audio adjustment and profile system |
CN110809457A (zh) | 2017-03-01 | 2020-02-18 | 米拉基创新智库有限公司 | 冷冻疗法 |
US20180271767A1 (en) | 2017-03-21 | 2018-09-27 | Zeltiq Aesthetics, Inc. | Use of saccharides for cryoprotection and related technology |
JP7085762B2 (ja) | 2017-04-05 | 2022-06-17 | ミラキ イノベーション シンク タンク エルエルシー | 低温スラリ閉じ込め |
US11439532B2 (en) | 2017-04-05 | 2022-09-13 | Miraki Innovation Think Tank Llc | Point of delivery cold slurry generation |
US10500342B2 (en) | 2017-08-21 | 2019-12-10 | Miraki Innovation Think Tank Llc | Cold slurry syringe |
US11523855B2 (en) | 2018-09-28 | 2022-12-13 | Team Neuro LLC | Spinal pain management system and method |
WO2020072979A1 (en) | 2018-10-04 | 2020-04-09 | Miraki Innovation Think Tank Llc | Slurry and solution compositions |
AU2019355657A1 (en) | 2018-10-04 | 2021-05-13 | Miraki Innovation Think Tank Llc | Methods of treating subcutaneous fat layers |
SG11202103516SA (en) | 2018-10-10 | 2021-05-28 | Miraki Innovation Think Tank Llc | Systems and methods for generating slurry |
WO2020077090A1 (en) | 2018-10-10 | 2020-04-16 | Miraki Innovation Think Tank Llc | Systems and methods of generating slurry for injection |
WO2020077072A1 (en) | 2018-10-12 | 2020-04-16 | Miraki Innovation Think Tank Llc | Cold solution for fat reduction |
US20220273569A1 (en) | 2019-07-24 | 2022-09-01 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
US20210038277A1 (en) | 2019-08-07 | 2021-02-11 | Christopher M. Shaari | Systems and methods for cryogenic treatment of headache |
WO2021055544A1 (en) | 2019-09-17 | 2021-03-25 | Arrinex, Inc. | Apparatus and methods for improved nasal cavity treatments |
EP4081746A4 (en) | 2019-12-24 | 2024-01-17 | Miraki Innovation Think Tank Llc | SUBSTANTIALLY SOLID SOLUTION, SYSTEMS AND METHODS FOR PRODUCING A SUBSTANTIALLY SOLID SOLUTION AND METHODS FOR ADMINISTRATION THEREOF |
US20230046673A1 (en) | 2019-12-26 | 2023-02-16 | Miraki Innovation Think Tank Llc | Treatment of obstructive sleep apnea |
US20230086345A1 (en) | 2020-01-23 | 2023-03-23 | The General Hospital Corporation | Novel method of enhanced drug delivery to the nervous system |
CA3168812A1 (en) | 2020-02-19 | 2021-08-26 | Cryosa, Inc. | Systems and methods for treatment of obstructive sleep apnea |
WO2021195582A1 (en) | 2020-03-27 | 2021-09-30 | James Anthony Stefater, Iii | Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry |
US20210330927A1 (en) | 2020-04-27 | 2021-10-28 | Black Cat Medical Llc | Method of performing cryoneurolysis |
US20220071900A1 (en) | 2020-09-08 | 2022-03-10 | Brixton Biosciences, Inc. | Systems and methods for preparing and transporting an injectable slurry |
US20220211923A1 (en) | 2020-09-24 | 2022-07-07 | Everest Medical Innovation GmbH | Cryoprotective Compositions, Surgical Kits, and Methods for Protection of a Surgical Site During Cryosurgery |
US20220087250A1 (en) | 2020-09-24 | 2022-03-24 | Everest Medical Innovation GmbH | Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery |
US20220409428A1 (en) | 2021-06-23 | 2022-12-29 | Black Cat Medical Llc | Method of performing cryoneurolysis |
-
2015
- 2015-08-27 CN CN202111089224.0A patent/CN113813222A/zh active Pending
- 2015-08-27 CA CA2958769A patent/CA2958769A1/en active Pending
- 2015-08-27 WO PCT/US2015/047292 patent/WO2016033380A1/en active Application Filing
- 2015-08-27 CA CA2958768A patent/CA2958768C/en active Active
- 2015-08-27 AU AU2015308790A patent/AU2015308790B2/en active Active
- 2015-08-27 BR BR112017003111-6A patent/BR112017003111B1/pt active IP Right Grant
- 2015-08-27 SG SG11201701505RA patent/SG11201701505RA/en unknown
- 2015-08-27 EP EP15835807.7A patent/EP3185876B1/en active Active
- 2015-08-27 EP EP21200731.4A patent/EP3988105A1/en not_active Withdrawn
- 2015-08-27 US US15/505,042 patent/US20170274011A1/en not_active Abandoned
- 2015-08-27 PT PT158367805T patent/PT3185854T/pt unknown
- 2015-08-27 EP EP22189301.9A patent/EP4176885A1/en active Pending
- 2015-08-27 WO PCT/US2015/047301 patent/WO2016033384A1/en active Application Filing
- 2015-08-27 CN CN201580058714.0A patent/CN107106481A/zh active Pending
- 2015-08-27 BR BR112017003143-4A patent/BR112017003143B1/pt active IP Right Grant
- 2015-08-27 SG SG10201913564WA patent/SG10201913564WA/en unknown
- 2015-08-27 SG SG10201913572TA patent/SG10201913572TA/en unknown
- 2015-08-27 MX MX2017002274A patent/MX2017002274A/es unknown
- 2015-08-27 KR KR1020177008381A patent/KR102507789B1/ko active IP Right Grant
- 2015-08-27 DK DK15835807.7T patent/DK3185876T3/da active
- 2015-08-27 CN CN202310486158.3A patent/CN117064838A/zh active Pending
- 2015-08-27 DK DK15836780.5T patent/DK3185854T3/da active
- 2015-08-27 JP JP2017511718A patent/JP6707525B2/ja active Active
- 2015-08-27 PL PL15836780T patent/PL3185854T3/pl unknown
- 2015-08-27 SG SG11201701504WA patent/SG11201701504WA/en unknown
- 2015-08-27 CN CN201580046634.3A patent/CN106794138B/zh active Active
- 2015-08-27 KR KR1020177008393A patent/KR20170044199A/ko not_active Application Discontinuation
- 2015-08-27 ES ES15836780T patent/ES2898097T3/es active Active
- 2015-08-27 US US15/505,039 patent/US20170274078A1/en not_active Abandoned
- 2015-08-27 EP EP15836780.5A patent/EP3185854B1/en active Active
- 2015-08-27 MX MX2017002271A patent/MX2017002271A/es unknown
- 2015-08-27 JP JP2017511724A patent/JP6858698B2/ja active Active
- 2015-08-27 AU AU2015308794A patent/AU2015308794A1/en not_active Abandoned
-
2017
- 2017-02-10 ZA ZA2017/01048A patent/ZA201701048B/en unknown
- 2017-02-13 ZA ZA2017/01080A patent/ZA201701080B/en unknown
- 2017-02-20 MX MX2021007621A patent/MX2021007621A/es unknown
-
2019
- 2019-02-28 ZA ZA2019/01279A patent/ZA201901279B/en unknown
-
2020
- 2020-05-19 JP JP2020087596A patent/JP6903792B2/ja active Active
-
2021
- 2021-01-27 AU AU2021200481A patent/AU2021200481B2/en active Active
- 2021-03-01 US US17/188,359 patent/US11938188B2/en active Active
- 2021-03-17 JP JP2021042989A patent/JP7201727B2/ja active Active
- 2021-04-21 US US17/236,567 patent/US11826427B2/en active Active
- 2021-06-22 JP JP2021102827A patent/JP7240447B2/ja active Active
-
2023
- 2023-03-03 JP JP2023032656A patent/JP2023060133A/ja active Pending
- 2023-08-10 AU AU2023214304A patent/AU2023214304A1/en active Pending
- 2023-10-16 US US18/487,887 patent/US11964017B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4986079A (en) * | 1988-08-12 | 1991-01-22 | Hitachi, Ltd. | Apparatus and method of generating coldness |
US6430957B1 (en) * | 1999-05-25 | 2002-08-13 | Agency Of Industrial Science & Technology Ministry Of International Trade & Industry | Method and apparatus for thermal transportation using polyvinyl alcohol |
US20020107199A1 (en) * | 2000-12-05 | 2002-08-08 | Allergan Sales, Inc. | Methods of administering botulinum toxin |
US20130190744A1 (en) * | 2010-02-15 | 2013-07-25 | The General Hospital Corporation | Methods and devices for selective disruption of visceral fat by controlled cooling |
Non-Patent Citations (1)
Title |
---|
Han Efficacy and safety of high concentration lidocaine for trigeminal nerve block in patients with trigeminal neuralgia, International Journal Clin Pract, 208, Feb, 62(2), pages 248-54, Abstract Only * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11826427B2 (en) | 2014-08-28 | 2023-11-28 | The General Hospital Corporation | Compositions and methods for treatment of neurological disorders |
US11938188B2 (en) | 2014-08-28 | 2024-03-26 | The General Hospital Corporation | Injectable slurries and methods of manufacturing and using the same |
US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
US11964017B2 (en) | 2014-08-28 | 2024-04-23 | The General Hospital Corporation | Compositions and methods for treatment of neurological disorders |
US11564830B2 (en) | 2016-02-26 | 2023-01-31 | The General Hospital Corporation | Medical ice slurry production and delivery systems and methods |
US11324673B2 (en) | 2016-11-18 | 2022-05-10 | Miraki Innovation Think Tank Llc | Cosmetic appearance of skin |
US20200046552A1 (en) * | 2017-03-01 | 2020-02-13 | Miraki Innovation Think Tank Llc | Cryotherapies |
US11439532B2 (en) | 2017-04-05 | 2022-09-13 | Miraki Innovation Think Tank Llc | Point of delivery cold slurry generation |
US11446178B2 (en) | 2017-04-05 | 2022-09-20 | Miraki Innovation Think Tank Llc | Cold slurry containment |
US11241541B2 (en) | 2017-08-21 | 2022-02-08 | Miraki Innovation Think Tank Llc | Cold slurry syringe |
US20240058267A1 (en) * | 2018-10-04 | 2024-02-22 | Miraki Innovation Think Tank Llc | Slurry and solution compositions |
US20210369612A1 (en) * | 2018-10-04 | 2021-12-02 | Miraki Innovation Think Tank Llc | Slurry and solution compositions |
WO2021016457A1 (en) | 2019-07-24 | 2021-01-28 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
WO2021151019A1 (en) | 2020-01-23 | 2021-07-29 | The General Hospital Corporation | Novel method of enhanced drug delivery to the nervous system |
US11819451B2 (en) | 2020-07-10 | 2023-11-21 | C° Change Surgical Llc | Injectable slush feed supply |
WO2022016015A1 (en) * | 2020-07-15 | 2022-01-20 | Lyotip, Inc. | Formulations for tetracaine and lidocaine |
US11241330B1 (en) | 2021-04-02 | 2022-02-08 | Brixton Biosciences, Inc. | Apparatus for creation of injectable slurry |
WO2022261494A1 (en) * | 2021-06-11 | 2022-12-15 | Brixton Biosciences, Inc. | Methods of creating a slurry using liposome emulsions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11964017B2 (en) | Compositions and methods for treatment of neurological disorders | |
US11504322B2 (en) | Injectable slurries and methods of manufacturing the same | |
US20230338276A1 (en) | Injectable slurries and methods of manufacturing the same | |
Schepis | The tuberous sclerosis complex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |